Skip to Main Content

Investors are infatuated lately with preclinical biotech companies going public.

Six of these very young biotechs have managed successful initial public offerings this year, despite not yet securing regulators’ permission to start human clinical trials. By comparison, one preclinical biotech was able to go public last year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.